

Policy for the development, approval and implementation of Patient Group Directions (PGDs) for use across BNSSG



Please complete the table below:	
Policy ref no:	18
Responsible Executive Director:	Peter Brindle (Medical Director, Clinical Effectiveness)
Author and Job Title:	Debbie Campbell (Deputy Director, Medicines Optimisation), Michelle Jones (Senior Medicines Optimisation)
Date Approved:	January 2019
Approved by:	Chief Executive, NHS Bristol, North Somerset & South Gloucestershire CCGs
Date of next review:	January 2021

	Yes/No/NA	Supporting information
Has an Equality Impact Assessment Screening been completed?	Yes	See Appendix F
Has the review taken account of latest Guidance/Legislation?	Yes	NICE PGD MPG2 updated March 2017
Has legal advice been sought?	n/a	
Has HR been consulted?	n/a	
Have training issues been addressed?	Yes	Competency and training addressed in section 4.4
Are there other HR related issues that need to be considered?	No	
Has the policy been reviewed by JCC?	n/a	
Are there financial issues and have they been addressed?	No	
What engagement has there been with patients/members of the public in preparing this policy?	n/a	
Are there linked policies and procedures?	No	
Has the lead Executive Director approved the policy?	Yes	Approved by Peter Brindle
Which Committees have assured the policy?	BNSSG DTC	
Has an implementation plan been provided?	Yes	See appendix G
How will the policy be shared with: <ul style="list-style-type: none"> • Staff? • Patients? • Public? 		The policy will be shared via email and will be available on the intranet
Will an audit trail demonstrating receipt of policy by staff be required; how will this be done?	Yes	This will be done by asking recipients to respond to the email to confirm that have read and understood

Contents



Policy for the development approval and implementation of Patient Group Directions (PGDs) across BNSSG	5
1. Introduction	5
1.1. Background.....	5
1.2. Where can PGDs be used	6
1.3. When are PGDs not required?	6
1.4. When is use of a PGD inappropriate?	7
1.5. Drugs requiring special consideration.....	7
1.5.1. Use Outside the terms of Summary of Product Characteristics.....	8
1.5.2. Newly Licensed drugs subject to special reporting arrangements (Black Triangle Drugs ▼)	8
1.5.3. Antimicrobial drugs.....	8
1.5.4. Controlled Drugs (CDs)	8
1.6. Who can use a PGD?	9
2. Purpose and scope	9
3. Approval Group.....	10
4. Process for development of PGDs.....	10
4.1. Proposals for PGD Development.....	10
4.2. Working Group for PGD development	12
4.3. Template for development of PGDs.....	12
4.4. Competency assessment for operating under the PGD.....	13
5. Process for approval of PGDs.....	13
5.1. PGD authorisation Group	13
5.2. PGD document database	14
5.3. Database of authorised practitioners	14
5.4. Production and distribution of PGDs.....	14
5.5. PGD review process	15
6. Responsibility of authorised practitioners.....	16
6.1. Criteria for the administration and/or supply of medicines	17
6.2. Patient counselling.....	17
6.3. Record Keeping.....	17
6.4. Security and storage of medicines.....	18
6.5. Premises.....	19



6.6. Indemnity insurance.....	19
6.7. Monitoring compliance and effectiveness	19
7. Appendices	21
Appendix A: BNSSG Services and Commissioners	21
Appendix B: Proposal for Development of a Patient Group Direction (PGD)	23
Appendix C: List of community provider PGD leads.....	26
Appendix D: PGD template	27
Appendix E: PGD extension letter	32
Appendix F: Equality Impact Assessment Screening	34
Appendix G: Corporate Policy Implementation Plan Template.....	37
8. References.....	39
Acknowledgments.....	39



Policy for the development approval and implementation of Patient Group Directions (PGDs) across BNSSG

1. Introduction

This policy outlines the approach to be taken by Bristol, North Somerset and South Gloucestershire (BNSSG) CCG for the development, approval, and implementation of patient group directions (PGDs) for use by authorised healthcare professionals working in providers that are directly commissioned by the NHS and local authorities. This Policy has been written to take into account the National Institute of Health and Care Excellence (NICE) Good Practice Guidance (GPG2) on Patient Group Directions (published August 2013, updated March 2017). The scope of this policy is outlined in section 2.0.

1.1. Background

The preferred method for patients to receive medicines is for prescribers to provide care for individual patients on a one-to-one basis. However, in some cases, it may be necessary, or more convenient for a patient to receive a medicine directly from another healthcare professional. There are several legal options for prescribing, supplying and/or administering medicines:

- Independent prescribing: the prescriber (a doctor, dentist or non-medical independent prescriber) takes responsibility for the clinical assessment of the patient, establishing a diagnosis, the clinical management needed, and prescribing;
- Supplementary prescribing: a voluntary partnership between a doctor or dentist and a supplementary prescriber, to prescribe within an agreed patient-specific clinical management plan with the patient's agreement;
- Patient Specific Directions (PSDs): written instructions, signed by a doctor, dentist, or non-medical prescriber for a medicine to be supplied and/or administered to a named patient after the prescriber has assessed the patient on an individual basis. PSDs can be used for a group of patients, all of whom should be named on the direction. PSDs are direct instructions and do not require an assessment of the patient by the health care professional instructed to supply and/or administer. Writing a PSD is a form of prescribing. The professional administering medication under PSD should be aware that they must ensure that the medication is appropriate for the patient and in line with NICE and other local guidance.
- Patient Group Directions (PGDs): written instructions for the supply and/or administration of specified prescription-only (POM) or pharmacy (P) medicine(s), by named, authorised, registered health professionals, to a pre-defined group of patients needing prophylaxis,

or treatment for a condition described in the PGD, without the need for a prescription, or an instruction from a prescriber (Health Service Circular HSC 2000/026). Using a PGD is not a form of prescribing;

- There are some exemptions from medicines legislation, for example
 - A range of exemptions enable certain groups of health professionals, such as chiropodists and podiatrists, midwives, paramedics, optometrists, to sell, supply and/or administer particular medicines directly to patients;
 - Occupational health schemes;
 - Treatment of pandemic disease;
 - In life threatening situations certain medicines are exempt from medicines legislation, e.g. adrenaline (epinephrine)

1.2. Where can PGDs be used

PGDs can be used in all areas in which NHS healthcare is directly provided, and where services in the private, voluntary or charitable sector are NHS funded.

PGDs do not extend to independent and public sector care homes or independent sector schools that provide healthcare entirely outside the NHS.

The majority of clinical care involving supplying and/or administering medicines should be provided on an individual, patient-specific basis. Therefore, having medicines prescribed on a prescription is considered the best route.

1.3. When are PGDs not required?

A PGD is unnecessary:

- If an exemption exists under the Medicines Act, such as:
 - Exemptions for paramedics, orthoptists, midwives and chiropodists. These exemptions allow these registered health professionals to administer or supply certain specified medicines within their scope of practice and competency without the directions of a doctor.
 - Exemptions for administration of certain parenteral medicines for the purpose of saving life in an emergency e.g. adrenaline.
 - Occupational Health Schemes
- If the medicine involved is on the General Sales List (classified as GSL)
- If the medicines to be administered are P medicines (a PGD is needed for supply of Ps). However some individual provider's medicines policies may require PGDs for both supply and administration of Ps and GSLs as PGDs are considered to be a method to assure patient safety that is more rigorous than procedures and protocols. However, this is a local decision and may not always apply or be appropriate.
- For medical gases: these are not usually classified as POMs
For dressings, appliances, medical devices, or chemical agents: these are not legally classed as medicines.

1.4. When is use of a PGD inappropriate?

The following **must not** be included in a PGD:

- Unlicensed medicines, including:
 - The mixing of two licensed medicines to form a new (unlicensed) product, unless one is a vehicle for administration, such as water for injection;
 - Special manufactured medicines;
- Radiopharmaceuticals;
- Anabolic steroids, and any injectable preparation used for treating addiction;
- Abortifacients, such as mifepristone.

A PGD should not be used when it is reasonable to expect that a prescription (FP10), or a PSD could be written in advance. PGDs should not be used to circumvent the repeat prescribing systems used in general practice. In addition PGDs should not be used for minor self-limiting conditions where the patient can reasonably self-care and purchase the medicine over-the-counter.

The NICE Good Practice Guidance recommends that there are some clinical situations in which alternatives to PGDs should be used, for example:

- For management of long-term conditions, such as hypertension or diabetes;
- Where uncertainty remains about the differential diagnosis, particularly when further investigations or diagnostic tests are needed, for example erectile dysfunction;
- Where the medicine needs frequent dosage adjustments, or frequent or complex monitoring, for example anticoagulants or insulin

The Specialist Medicines Service 'to PGD or not to PGD' is a tool which may be used to aid decision making and help to consider whether a Patient Group Direction (PGD) is appropriate for an area of practice that involves the supply or administration of medicines,

1.5. Drugs requiring special consideration

Certain medicines will require special consideration before inclusion in a PGD and some are restricted by legislation.

1.5.1. Use Outside the terms of Summary of Product Characteristics

Medication, which is licensed, but used outside the terms of its product licence ('off label'), can be included in a PGD. However, such use must be exceptional, justified by best practice, and the status of the product must clearly be described and communicated to the patient

Information should be provided to the PGD Approval Group to demonstrate that there is acceptable evidence for the use of that product for the intended indication, e.g. follows nationally agreed guidelines, such as the Joint Committee on Vaccination and Immunisation (JCVI).

1.5.2. Newly Licensed drugs subject to special reporting arrangements (Black Triangle Drugs ▼)

Newly licensed drugs should only be considered in exceptional circumstances, when clearly justified by best clinical practice. Treatment guidelines must be followed and the PGD must clearly state the status of the product.

1.5.3. Antimicrobial drugs

Antimicrobial resistance is a major public health concern. The use of antibiotics and other antimicrobials in PGDs must, therefore, be given careful consideration. Inclusion in a PGD should only be considered where absolutely necessary and where measures to combat resistance will not be compromised. Use should be in line with BNSSG antimicrobial guidelines and the PGD should be regularly reviewed. A microbiologist should be involved in the drawing up of the PGD if the BNSSG guidelines do not cover the PGD indication.

1.5.4. Controlled Drugs (CDs)

Only certain controlled drugs are legally eligible to be included in a PGD, in accordance with The Misuse of Drugs Regulations (2001):

- Morphine and diamorphine may be used by registered nurses and pharmacists only, for the immediate necessary treatment of a sick or injured person (except for treating addiction)
- Midazolam
- Drugs in Schedule 4 except anabolic steroids and injectables for treating addiction.
- Any drug in Schedule 5, including codeine.

1.6. Who can use a PGD?

PGDs must only be used by the following registered health professionals:

- Chiropodists and podiatrists
- Dental hygienists
- Dental therapists
- Dietitians
- Midwives
- Nurses
- Occupational therapists
- Optometrists
- Orthoptists
- Orthotists and prosthetists
- Paramedics
- Pharmacists
- Physiotherapists
- Radiographers
- Speech and language therapists

Individual health professionals must be named and authorised to practice under a PGD.

2. Purpose and scope

This policy sets out the processes to be followed within Bristol, North Somerset, and South Gloucestershire (BNSSG) for the development and approval of PGDs for treatment of NHS patients by authorised healthcare professionals working for provider organisations directly commissioned by BNSSG Clinical Commissioning Group (NS CCG), Bristol City Council, North Somerset Council (NSC), South Gloucestershire Council, NHS England's Bristol, North Somerset, Somerset and South Gloucestershire (BNSSG) Area Team. BNSSG commissioners will only authorise PGDs for use within the BNSSG Region. Refer to Appendix A: BNSSG Services and Commissioners for details of service commissioners.

This policy covers the following practitioners and organisations (this list is not exhaustive):

- Practice nurses and pharmacists working in GP practices in Bristol, South Gloucestershire and North Somerset;
- Pharmacists working in community pharmacies that provide NHS services in Bristol, South Gloucestershire and North Somerset;
- Nurses and other authorised healthcare professionals working for providers that are directly commissioned by BNSSG CCG, NSC, SGC and BCC.

This policy applies to independent contractors and providers commissioned by BNSSG CCG, NS CC, Bristol CC, SG CCNSC, NHS England BNSSSG Area Team, who wish to develop and/or work under a PGD when treating NHS patients under the terms of a contract.

Acute trusts currently fall outside the scope of this policy, as they have their own internal authorisation processes and do not require the CCG to sign as they are legally authorised to approve PGDs.

However, there is a process in place to align PGDs, so there is single PGD per drug and indication that can be used across organisational boundaries. This is progressing through the Medicines Optimisation Sustainability and Transformation Plan (STP) programme of work.

Note: Where the PGD is developed and supplied to the provider e.g. immunisation PGDs given to community providers or GP practices, these organisations must sign the PGD to adopt it for use. The commissioning organisation may sign on behalf of a group of providers e.g. immunisation PGD are signed by NHS SW to GP practices and community providers within their area. This is required by the legislation governing PGDs. This also applies for community pharmacies that use PGDs that have been authorised by the commissioner.

3. Approval Group

PGDs must be authorised only by an appropriate authorising body in line with legislation. Commissioning and provider organisations may be authorising bodies. In the NHS in England, the organisations that are legally authorised to approve PGDs are:

- Clinical commissioning groups (CCGs);
- Local authorities;
- NHS trusts or NHS foundation trusts;
- Special health authorities;
- NHS England.

Refer to Appendix A: BNSSG Services and Commissioners, for details of who should be involved with PGD authorisation for each of the BNSSG services.

4. Process for development of PGDs

4.1. Proposals for PGD Development

In the majority of cases, the most appropriate clinical care should be provided on an individual basis by a prescriber to a specific named patient. The use of PGDs should be reserved for those situations where they would offer benefit to patient care without compromising safety. For a clinical condition to be catered

for by a PGD, the presenting characteristics and treatment requirements must be sufficiently consistent. Examples of such groups are:

- Those requiring immunisation as part of a national programme;
- Those requiring sexual and reproductive health services;
- Those requiring treatment of a minor injury e.g. analgesia

Service Leads considering the development of a PGD for use should consider whether a PGD is needed using the NHS Specialist Pharmacy Service PGD resources. Requests for PGDs can be put forward using the attached documentation (

Appendix B: Proposal for Development of a Patient Group Direction (PGD))

Requests for PGDs should be sent to the community provider service leads. Details of Service Leads names and contact details can be found in (Appendix C: List of community provider PGD leads).

The provider service lead should review the request to ensure it is appropriate and send the request to the Medicines Optimisation PGD working group.

Requests for new PGDs where the provider is a community pharmacy or third sector provider, and commissioned by Bristol, North Somerset or South Gloucestershire Council or BNSSG CCG should submit requests directly to the Medicines Optimisation PGD working group.

Requests for new PGDs from GP practices should be directed to NHS England's Area Team.

The proposal should include consideration of the other available options for the supply and administration of medicines (e.g. non- medical prescribing). It should also consider the PGDs potential impact on equality. The proposal will be considered and development of the PGD prioritised depending on:

- The appropriateness;
- Benefit to patients;
- Risk to patients;
- Financial implications
- Staff resources (both for development and implementation).

If the development of the PGD is agreed the Service Lead will be informed of the expected timescales for the development and implementation of the PGD.

The availability of resources required for development and implementation of PGDs should be considered early in the commissioning process of a service. If the commissioned organisation does not have this resource the funding for provision will have to be resolved between the provider and the commissioner.

4.2. Working Group for PGD development

Legislation does not specify who must be involved in developing PGDs. The Health Service Circular (HSC 2000/026) states that PGDs 'should be drawn up by a multidisciplinary group involving a doctor, a pharmacist and a representative of any other professional group expected to supply medicines under the PGD'.

The NICE Good Practice Guideline (GPG) expands on this and states that a PGD working group should be established for each individual PGD, although the same group may be responsible for developing a number of PGDs.

The responsibility for the membership of the PGD Working Group will lie with the provider organisation, and it is expected that:

- The PGD Working Group is set up in line with GPG2 recommendations.
- Membership reflects recommendations of GPG2, including appropriate input from relevant primary care practitioners.
- The roles and responsibilities of each member of the PGD Working Group, how they work together to develop the PGD, and how the group operates, will be determined by the PGD Working Group.
- Individual PGDs will be developed by a named lead author, agreed by the PGD Working Group, who will have overall responsibility for clinical content.
- Where appropriate it seeks input from Public Health England and NHS England
- It takes into consideration the recommendations of the NICE competency framework for people developing, reviewing or updating PGDs

Additional expertise may be needed, for example:

- A specialist with appropriate expertise, such as a local specialist in microbiology for PGDs containing an antimicrobial.

All stakeholders in the development of the PGD should be identified by the PGD Working Group and consulted on the development of the PGD. Draft PGDs will be sent to representatives of the professional groups who will be operating under the PGD for comment and for identification of potential issues that may arise when PGDs are implemented.

4.3. Template for development of PGDs



PGDs should be developed using the NICE template for PGDs (

Appendix D: PGD template).

It is the responsibility of the lead author to manage all drafts of the PGD(s) from initial development to approval. Version control must be maintained, including dates of each draft, and version numbers, so that changes made can be tracked

4.4. Competency assessment for operating under the PGD

The PGD Working Group alongside the Service Lead should consider and agree training and competency requirements for staff wishing to operate under the PGD, in line with the NICE competency framework for health professionals using PGDs, including

- Understanding of the requirements of individual PGDs;
- Knowledge of pharmacology of the drug to be included in the PGD;
- Knowledge of relevant legislation relating to use of the medicines and medical conditions and the content will be agreed by the PGD working group.

5. Process for approval of PGDs

5.1. PGD authorisation Group

Approved PGDs require the signature of the authorising body and should also be signed by a senior pharmacist and a senior doctor (or dentist). It is also good practice for the lead health professional working under the PGD to also sign.

The doctor (or dentist) and pharmacist signatories must establish that the clinical and pharmaceutical content are accurate, and supported by the best available evidence.

When signing a PGD as a commissioner, the commissioner lead must establish that:

- Processes and governance arrangements have been followed;
- All legal requirements have been met.

Note that electronic signatures are acceptable:

<https://www.sps.nhs.uk/articles/questions-electronic-systems-and-pgds/>, however, attaching a scanned picture of a signature is not acceptable.

The Approval Group will assess implementation requirements and develop a communications plan to support the dissemination of PGDs (see 6.4 below). The group will identify an appropriate person who is responsible for ensuring that this occurs.

Protected copies of PGDs (as PDFs) developed and authorised will be emailed directly to the provider/ council who should post on the relevant websites.

For each PGD, the provider organisation should:

- Identify a senior, responsible person from within the service to authorise named, registered health professionals to practise under the PGD;
- Ensure that authorised health professionals have signed the appropriate documentation.

5.2. PGD document database

A database of all approved PGD documents will be maintained by the Provider Organisation. This includes GP practices. The database will be maintained on the appropriate Medical Directorate/ GP practice drive. Each PGD will be given a unique PGD identifier and will be included on the summary front page of the relevant PGD. The expiry date for each PGD will also be recorded on the database.

Copies of expired PGD master (original signed) documents will be kept as for all other patient records. For adults all PGD documents must be kept for a minimum of 10 years, and those that apply to children must be kept for 25 years.

5.3. Database of authorised practitioners



The names of the healthcare professionals who have been authorised to operate under PGDs must be kept by the service lead within the provider organisation. The Medicines Optimisation Team, provider organisation or Local Authority may request details of authorised practitioners.

It is the responsibility of the service lead for the provider organisation that is using the PGD to ensure that the list is updated to reflect both new staff authorised to operate under the PGD and staff no longer authorised to operate under the PGD. Examples of service leads include:

- Lead GP within a GP practice, who would authorise individual practice nurses;
- Superintendent pharmacist of a small, local chain of pharmacies, who would authorise individual pharmacists (managers and locums).
- Clinical and Operational Lead for a particular service e.g. MIU
- Responsible Clinician e.g. No Worries

5.4. Production and distribution of PGDs

To ensure version control the provider will only distribute PGDs through signposting to the relevant website. Provider organisations will **NOT** email copies to any service.

When any new or amended PGD is posted onto the website, the organisation responsible for the development of the PGD will arrange for the relevant providers to be notified by email. Where these are primary medical care providers then this will be done through the authorising body. It is the responsibility of each provider to ensure that this information is cascaded to all relevant staff.

A copy, including the signatory page should be printed off by the service lead/manager, and this will be used to prepare individual copies for staff to refer to. The service lead/manager is responsible for ensuring the completeness and quality of the final copy for use by staff.

Each individual member of staff working to a PGD must be authorised by name to work to that PGD and sign and date the document to agree to work under that PGD at that time. A senior practitioner in the service or service manager must ensure that only staff who are competent to work under the PGD are signed up to it: There is no requirement for the individual authorisation to be kept as a hard copy; where systems exist for the declaration of competence and maintenance of records, this is acceptable, for example PharmOutcomes.

The original signed copy with signatures of the authorised healthcare professionals should be kept for a minimum of 10 years, if treatment relates to adults, and those that apply to children must be kept for 25 years.

The main content of a PGD (i.e. an unauthorised final copy), which contains no patient identifiable information or staff authorisation records, may be retained by

an organisation for up to 20 years for purposes of business planning/continuity if there is reason to do so (i.e. reference for future PGDs).

In the GP practice setting, it is the responsibility of the Senior Partner (or designated doctor/clinical lead) to ensure the competency, and to counter sign the documents for any nurse, or other authorised healthcare professional working under PGDs within the practice. The GP practice will keep these signed authorisations as both evidence of individuals' competency and as a record of staff authorised to use the PGD.

5.5. PGD review process

PGDs must have an expiry date, and must not be used beyond their expiry date, because any supply and/or administration of a medicine(s) would be without legal authorisation. The expiry date for a PGD should be considered and determined on a case-by-case basis with patient safety paramount. NICE recommend that this should be a maximum of 3 years from the date the PGD was authorised (or reauthorised following review).

In exceptional circumstances e.g. organisation or service transition, an extension to the expiry date may be applied for, to allow the PGD to be used without review and re-authorisation. Extension of expiry dates without review of a PGD is not without risk (e.g. licence of medicine may have changed/national guidance may have changed) but the organisation may deem this necessary where it is in the interests of patient safety; for example there may be a risk where withdrawing the PGD could result in significant service disruption and potential patient safety issues due to lack of access to medicines.

Where an extension is required the lead pharmacist should clinically check the PGD to ensure it would remain safe to use and contact the organisational signatory via email explaining the reasons why an extension to expiry date is required and the consequences of not having the extension. Where an extension is agreed this should be for an agreed period for no longer than one year. The total valid period of a PGD including the extension should not exceed three years.

Appendix E: PGD extension letter should be agreed and signed and provided to the service lead. It is important that the letter is brought to the attention of all of the individual healthcare professionals who currently operate under the PGDs.

Any proposed changes, including minor amendments, will require the PGD to go through the review process and be re-authorised. It is the responsibility of the lead author to initiate the review process in good time to ensure continuity of care. A senior doctor and pharmacist must be involved in the review. The review process should involve consultation with all stakeholders.

6. Responsibility of authorised practitioners

All staff in professional groups able to work under PGDs are expected to do so, where this is a requirement of the service and/or it is included in their job description. Each individual will have to sign an agreement to work to a PGD.

Authorised practitioners must only undertake the extended role under a PGD in circumstances where they are competent to assess all relevant aspects of the patient's clinical condition, take responsibility for supply and/or administration of the medicine and make related decisions. If the authorised practitioner is in any doubt about their competency they should not administer and/or supply in accordance with the PGD and should seek advice from their relevant professional body, their line manager or the clinical lead for the service.

A practitioner authorised to work under a PGD cannot delegate the responsibility to another person.

All authorised practitioners supplying and/or administering medicines under PGDs must be named and have written evidence of competence, training, knowledge, experience and continuing education relevant to the clinical condition/situation to which the PGDs apply. The practitioner must take personal responsibility for ensuring they maintain their competence and knowledge, and attend additional training when appropriate.

Practitioners should have a signed copy of the **current** PGD available for reference when supplying and/or administering a medicine.

Practitioners should keep a record of the supply and/or administration made under a PGD. This should be made available for audit purposes when necessary. The supply or administration must be attributable to an individual practitioner.

6.1. Criteria for the administration and/or supply of medicines

Supply and administration of the medicine must be strictly in accordance with the PGD and appropriate for the clinical condition. Evidence-based treatment guidelines should be used by the healthcare professional to inform clinical decision-making. The client must meet the eligibility criteria. Any variance from these criteria means that the client must be excluded, alternative arrangements made and this documented.

6.2. Patient counselling

The following should be discussed with the patient:

- Reason for the treatment;



- Why the medicines are supplied and/or administered;
- Counselling on correct use of the medicine according to PGD and label;
- The manufacturer's patient information leaflet (PIL) must be provided when medicines are supplied to patients. It is good practice to provide the PIL when administering a medicine. Discuss any queries that the patient/carer may have;
- Possible side effects, their management and when to seek medical help;
- Caution with interacting medicines;
- Advice on follow-up treatment and referrals.

6.3. Record Keeping

The following information must be recorded and ideally this would be electronically:

- Patient's details: name, condition presented, medical history;
- Patient assessment and diagnosis;
- Contra-indications to any medicines;
- Medicines which have caused allergic reactions or side effects;
- Allergies to the drug and/or excipients;
- Current and recent prescription medication, including over the counter (OTC) medicines and herbal preparations;
- Reasons for exclusion and referral;
- Medicine supplied and/or administered: name; form; strength; quantity; batch number; expiry date; information and advice given;
- Name and/or signature of the Health Care Professional providing treatment and supplying the medicine.

All records must be signed, dated and kept for 10 years after last attendance, or up to the patient's 25th birthday if longer than 10 years away. Records should be kept in the patient's notes and sent to the patient's GP, or as detailed in the individual PGD.

Details of administration of vaccines to children must be sent to the appropriate Child Health Information System.

Where available, an entry on the computer record under the healthcare professional's individual identification and password is an acceptable alternative.

6.4. Security and storage of medicines

Medicines must be stored in safe, secure, locked cupboards, or pharmaceutical refrigerators, in a secure lockable room away from public access following best practice principles (refer to any local policies regarding storage of medicines):

- Storage must be appropriate to the requirements for the medicine, e.g. refrigeration;

- Internal and external medicines must be stored separately;
- Flammables must be stored appropriately in a flammables cupboard.

There must be a secure system for the recording and monitoring of medicines used from which it should be possible to reconcile incoming stock and outgoing stock on a patient- by-patient named basis.

When a POM is supplied, the medicine must be supplied in an original pack obtained from an approved supplier. The contents of pre-packs should not be altered to suit individual patients. They should be advised to take the recommend course and return excess doses to their community pharmacy for destruction. Each pre-pack must be labelled with the following:

- Name of the medicine, form, strength and quantity;
- Directions for use, dose and frequency;
- Cautions and advisory labels;
- Additional warning 'to keep out of reach of children';
- Special handling or storage instructions;
- Batch number and expiry date;
- Name and address of the service provider.

At the point of supply the Healthcare professional must add both the name of the patient, and the date of issue.

In addition, the manufacturer's patient information leaflet (PIL) must be provided each time a medicine is supplied to comply with European Council Directive 2004/27/EC. Arrangements for the collection of prescription charges, or identifying clients who are exempt from such charges, need to be in place to comply with NHS Standing Financial Orders.

6.5. Premises

The service should be provided from premises with adequate facilities, which provide the necessary confidentiality and conform to any requirements stipulated in the PGD.

6.6. Indemnity insurance

Those employed, (as opposed to being self-employed), whether within or outside the NHS, will almost certainly be covered for these purposes. Individual practitioners should have their own Professional Indemnity Insurance and ensure that the insurance provider is aware that they are operating under PGDs. Practitioners who are members of a professional organisation, or trades union, may also be covered additionally by this body. Most employers provide vicarious liability insurance to cover the acts or omissions of their employees, but practitioners must check that they are covered. The service lead/manager authorising staff to operate under PGDs within their service

should also ensure that their professional indemnity insurance covers their authorising PGDs for use within their service

6.7. Monitoring compliance and effectiveness

It is a legal requirement to keep records of administration and/or supply under PGD for audit purposes. Care provided under a PGD must be audited. It is recommended that an audit of PGDs is undertaken annually. For new staff, practice should be audited six months after commencing the post.

Audits on the use of PGDs will be initiated and carried out by Service Leads/Managers to ensure compliance with procedures. The results of the audit should be shared within the service and reported to the PGD Approval Group on request.

The audit must include:

- Reason for administering or supplying under PGD;
- Record of assessment criteria (e.g. appropriate history taking required for decision making);
- Reason for not making supply/administering and action taken;
- History of allergy recorded in notes;
- Advice given: verbal and written.

PGDs will not normally be accepted for revision unless an audit report has been provided (details above).

The NHS Specialist Pharmacies Service provide example [audit tools](#) which may be adapted to conduct an annual audit of PGDs

7. Appendices

Appendix A: BNSSG Services and Commissioners

Service	Provider	Commissioning Organisation	PGD Authorisation		
			Doctor	Pharmacist	Commissioner
MSK service	NSCP	BNSSG CCG	Medical Advisor NSCP	Senior Pharmacist NSCP	Deputy Director (Medicines Optimisation) BNSSG CCG
Community nurses	NSCP	BNSSG CCG	Medical Advisor NSCP	Senior Pharmacist NSCP	Deputy Director (Medicines Optimisation) BNSSG CCG
Community Pharmacy Sexual Health Service	Community pharmacies	NSC	Medical Director BNSSG CCG	Deputy Director (Medicines Optimisation) BNSSG CCG	DPH NSC
Community Pharmacy Varenicline PGD service	Community pharmacies	NSC	Medical Director BNSSG CCG	Deputy Director (Medicines Optimisation) BNSSG CCG	DPH NSC
Immunisation and vaccinations (inc flu)	GP practices	NHS England	Medical Director NHS England	Senior Pharmacist NHS England	Director of Nursing NHS England
BrisDoc Out of Hours Services	BrisDoc	BNSSG CCG	Medical Director BrisDoc	Senior Pharmacist BNSSG CCG	Deputy Director (Medicines Optimisation) BNSSG CCG
BrisDoc Walk-in Centre	BrisDoc	BNSSG CCG	Medical Director BrisDoc	Senior Pharmacist BNSSG CCG	Deputy Director (Medicines Optimisation)

					BNSSG CCG
Urgent Care Centre	Bristol Community Health	BNSSG CCG	Medical Advisor BNSSG CCG	Senior Pharmacist BCH	Deputy Director (Medicines Optimisation) BNSSG CCG
Musculoskeletal assessment and treatment service	Bristol Community Health	BNSSG CCG	Medical Advisor BNSSG CCG	Senior Pharmacist BCH	Deputy Director (Medicines Optimisation) BNSSG CCG
Community rehabilitation services	Bristol Community Health	BNSSG CCG	Medical Advisor BNSSG CCG	Senior Pharmacist BCH	Deputy Director (Medicines Optimisation) BNSSG CCG
Practice and community nurses	NHS England and Bristol Community Health	Bristol City Council	Medical Director NHS England Medical Director BNSSG CCG	Senior Pharmacist BNSSG CCG	Deputy Director (Medicines Optimisation) BNSSG CCG
Yate MIU	Sirona care & health	SG CCG	Medical Director Sirona Care & healthcare	Senior Pharmacist Sirona Care & healthcare	Deputy Director (Medicines Optimisation) BNSS CCG
Physiotherapy & other community services	Sirona care & health	SG CCG	Medical Director Sirona Care & healthcare	Senior Pharmacist Sirona Care & healthcare	Deputy Director (Medicines Optimisation) BNSS CCG

Appendix B: Proposal for Development of a Patient Group Direction (PGD)

This form must be completed before the development of any patient group direction to ensure all aspects of the PGD are considered prior to full development. Once completed, it should be submitted to the medicines Optimisation PGD Working Group for consideration, this group will then agree or decline the development of the patient group direction.

Title of patient group direction	
Medicines to be supplied or administered under this PGD (including dosage, quantity, formulation, strength, route and duration of treatment)	
What is the clinical situation that this PGD would be used in? to be treated	
Which patients will be included in treatment? (Specify age)	
In what setting would the PGD be used?	
Legal status of medicines (POM, P, GSL)	
BNSSG formulary status of medicines www.bnssgformulary.nhs.uk	Green / Blue / Amber / Red / Non-formulary
Staff groups to be operating under this PGD (e.g. nurses, physiotherapists etc)	
How is the medicine currently supplied?	
Why is a PGD needed for supply or administration of this medicine(s)?	



<p>What other methods of supply have been considered?</p> <p>Why is a PGD the most suitable method of supply?</p>	
<p>What are the benefits of supplying this medicine using a PGD?</p>	
<p>What are the implications or consequences of not developing this PGD?</p>	
<p>What evidence is there to support the use of this medicine? E.g. NICE guidelines etc.</p>	
<p>Is this a service that is currently commissioned?</p>	
<p>Who commissions the service? E.g. CCG, Local Authority, NHS England</p>	
<p>What are the financial implications of implementing this PGD? (including drug costs, training etc?)</p>	
<p>What is the potential impact on equality? (Include both negative and positive impact)</p>	
<p>What training will be needed to supply/administer medicines using this PGD? How will these training needs be met?</p>	



How will ongoing training and competence be undertaken and assessed?	
Who will be responsible for writing and updating the PGD?	
Form completed by Base Contact details	
Service Lead / Manager signature Date	

The above PGD has been approved for development by the Medicines Optimisation PGD working group.	YES / NO
Comments	
Date	

Appendix C: List of community provider PGD leads

Organisation	Service Lead name	Position	Email address
NSCP	Kate Ellis	Lead Pharmacist	Kate.ellis5@nhs.net
BCH	Ana Seoane	Head of Medicines Management	a.seoane@nhs.net
Sirona	Joanne Clarke	Medicines Optimisation Pharmacist	Joanne.Clarke@sirona-cic.org.uk
Brisdoc WIC	Michelle Whittle	Nurse Manager	michellewhittle@nhs.net
Brisdoc OOH	Frank Burge	Head of Nursing	Frank.burge@nhs.net

Appendix D: PGD template

Insert logo of authorising body

Additional organisational logo(s) as agreed locally

This Patient Group Direction (PGD) must only be used by registered health professionals who have been named and authorised by their organisation to practice under it. The most recent and in date final signed version of the PGD should be used.

Patient Group Direction

for the supply and/or administration¹ of

Name of medicine

by registered health professional group(s) for

Condition/situation/patient group

in location/service/organisation

Version number:

¹ Delete as appropriate

Change history

Version number	Change details	Date

PGD development

Name	Job title and organization	Signature	Date
Lead author			
Lead doctor (or dentist)			
Lead pharmacist			
Representative of other professional group using PGD			
Other members of the PGD working group			

PGD authorisation

Name	Job title and organisation	Signature	Date
Senior doctor (or dentist)			
Senior pharmacist			
Senior representative of professional group using the PGD			
Person signing on behalf of authorising body			

PGD adoption by the provider²

Name	Job title and organisation	Signature	Date
Signatures to be determined locally, if relevant			

² Delete section if not relevant



Training and competency of registered health professionals

	Requirements of registered health professionals working under the PGD
Qualifications and professional registration	
Initial training	
Competency assessment	
Ongoing training and competency	

Clinical condition

Clinical condition or situation to which this PGD applies	
Inclusion criteria	
Exclusion criteria	
Cautions (including any relevant action to be taken)	
Arrangements for referral for medical advice	
Action to be taken if patient excluded	
Action to be taken if patient declines treatment	

Details of the medicine



Name, form and strength of medicine <i>Include ▼ for <u>black triangle medicines</u></i>	
Legal category	
Indicate any <u>off-label use</u> (if relevant)	
Route/method of administration	
Dose and frequency	
Quantity to be administered and/or supplied	
Maximum or minimum treatment period	
Adverse effects	
Records to be kept	

Patient information

Written information to be given to patient or carer	
Follow-up advice to be given to patient or carer	

Appendices

Appendix 1. Key references

<ol style="list-style-type: none"> 1. E.g. NICE guidance and the Summary of Product Characteristics 2.
--

Appendix 2 Health professionals' agreement to practise

The attached PGD is agreed for use at **[insert organisation]**. Agreed on behalf of the organisation by [insert name and job title].

This patient group direction is to be read, agreed to and signed by all health professionals to whom it applies. Patient Group Directions do not remove inherent professional obligations or accountability.

It is the responsibility of each professional to practice only within the bounds of their own competence and to ensure you are working from the current version of the PGD. If this PGD is an updated or replaced, ensure that all older versions are withdrawn from use with immediate effect.



Registered Health Care Professional:

By signing below I confirm that I understand the legal framework for the use of PGDs. I confirm that I have read and understood the PGD outlined above and am appropriately trained and competent to undertake administration of [insert medicine] in accordance with this PGD and within my professional code of conduct.

Name of health professional	Signature	Senior representative authorising health professional	Date

Other appendices may be added as agreed locally.



Appendix E: PGD extension letter

Dear _____,

Extension of validity of Patient Group Directions (PGDs) for [insert service] provided in [insert area]

We are aware that the PGD(s) currently in use at [insert service] have an expiry date of [insert date] and that full review and authorisation will not be completed by this date

The legislation currently allows for PGDs validity to be extended for a limited period if necessary. We therefore think that this is a sensible step given the issues that would be caused if [insert service] were unable to use these PGDs for a period of time.

This letter gives notice that the PGD(s) listed below will have their period of validity extended to the [insert date], by which time the updated versions will be available.

INDICATION	DRUG	CURRENT EXPIRY

The PGD(s) listed above have been reviewed by the pharmacist lead and it has been assessed that the PGDs remain safe to use and will not put service users at increased risk of harm.

A copy of this letter should be kept with the PGD records in all areas where healthcare professionals are working to these PGDs. It should also be brought to the attention of the individual healthcare professionals who operate under the PGDs currently.

If you have any queries, please contact [insert contact name and email address].
Yours sincerely,

On behalf of Bristol, North Somerset and South Gloucestershire CCG

**Doctor
(Name and role)**

**Pharmacist
(Name and role)**

**Organisation
(Name and role)**



Appendix F: Equality Impact Assessment Screening

Equality Impact Assessment Screening	
Query	Response
What is the aim of the document?	The policy provides a framework for the CCG and services directly commissioned by the CCG and Local Authority for use when developing, approving and implementing Patient Group Directions that are authorised by the CCG.
Who is the target audience of the document (which staff groups)?	Medicine Optimisation, Local Authority and Community Provider PGD leads
Who is it likely to impact on and how?	Staff Yes in that it describes the way in which staff are required to manage all processes from the development stage to the implementation stage of writing or reviewing PGDs. It does not have an impact on staff in terms of Equalities and Human Rights (see below)
	Patients Yes in that a PGD can aid improved access to medicine when appropriate.
	Visitors no
	Carers no
	Visitors no
	Other – governors, volunteers etc no

Does the document affect one group more or less favourably than another based on the 'protected characteristics' in the Equality Act 2010:	Age (younger and older people)	no
	Disability (includes physical and sensory impairments, learning disabilities, mental health)	no
	Gender (men or women)	no
	Pregnancy and maternity	no
	Race (includes ethnicity as well as gypsy travellers)	no
	Sexual Orientation (lesbian, gay and bisexual people)	no
	Transgender people	no
	Groups at risk of stigma or social exclusion (e.g. offenders, homeless people)	no



	Human Rights (particularly rights to privacy, dignity, liberty and non-degrading treatment)	no
--	---	----

Appendix G: Corporate Policy Plan Template

Implementation

Policy for the development, approval and implementation of patient Group direction (PGDs) for use across BNSSG

Policy Owner: Debbie Campbell

Target Group	Implementation or Training objective	Method	Lead	Target start date	Target End date	Resources Required
Clinical Policy Group	Ensure CPG review the policy and have an awareness of CCG's responsibilities in relation to the development, approval and implementation of PGDs that are authorised by the CCG. Ensure that CPG are assured that appropriate processes have been established.	Policy to be reviewed at Corporate Policy Review (CPR) Group Revised version	Deputy Director Medicines Optimisation		6 November 2018 10 December 2018	staff time, governing body time
Executive Directors	Ensure awareness of CCG processes and procedures as well as being aware of relevant legislation.	Policy to be reviewed and ratified at CE. May require ratification at GB depending on discussion at CE Added to the hub Policy to be placed on website	Deputy Director Medicines Optimisation		13 December 2018	staff time, executive directors time
Community Provider PGD Leads	Ensure awareness of CCG processes and procedures as well as being aware of relevant legislation.	Policy to be placed on website Circulate to relevant Medicines Optimisation staff, Medical Director (Clinical Effectiveness) and Community Provider PGD leads	Deputy Director Medicines Optimisation		Ongoing	staff time

And relevant Medicines Optimisation Staff						
--	--	--	--	--	--	--

8. References

1. The Human Medicines Regulations 2012. Amended April 2013. [Accessed online at <http://www.legislation.gov.uk/ukxi/2012/1916/contents/made>]
2. Health Service Circular. 2000. Patient Group Directions [England Only]. NHS Executive. [Accessed online at http://webarchive.nationalarchives.gov.uk/20120503185443/http://www.dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/@dh/@en/documents/digitalasset/dh_4012260.pdf]
3. NICE Medicines practice guideline. 2013 updated March 2017. Patient Group Directions. [accessed online at <https://www.nice.org.uk/Guidance/MPG2>]

Acknowledgments

This policy is based on the Policy for the Development, Approval and Implementation of Patient Group Directions (PGDs) for use in North Somerset.